Publication Date:
2007-11-16
Description:
Introduction Even mild renal dysfunction (e.g. creatinine 100 to 140 μmol/l) can be related to inadequate erythropoietin (EPO) response in patients with refractory anemia and bone marrow features compatible with dysplasia (Korte, Cogliatti et al. 2000). Overall, this seems not an infrequent mechanism (Fehr, Ammann et al. 2004) Therefore, patients with MDS bone marrow morphology and secondary bone marrow dysfunction due to EPO deficiency may be diagnosed as having a myelodysplatic syndrome (refracory anemia [RA] or even refractory anemia with ringed sideroblasts [RARS]). Patients and Methods We performed a single center, prospective, non-randomized pilot study to evaluate the potential benefit of EPO therapy in patients with refractory anemia, mild renal insufficiency and low EPO levels. Eligibility criteria were: hemoglobin (hb) concentrations
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink